Coleman Legal LLP Logo

Latest News

Newsletters

Defective Blocks Redress Coleman legal LLP

Defective Blocks

Defective Blocks newsletter and latest updates.

Read More

Mother and Baby Home Coleman legal LLP

Mother & Baby Homes

Mother and Baby Homes redress newsletter and latest updates.

Read More

CAMHS Misdiagnosis Coleman legal LLP

CAMHS Review

CAMHS newsletter and latest updates.

Read More

Rose Sweeney has over 30 years of experience dealing with personal injury claims and has worked alongside Dave Coleman for over 27 years.

Rose Sweeney specialises in Personal Injury law and regularly represents clients who have suffered injuries in road traffic accidents, workplace accidents, slips and trips, and industrial and occupational diseases. Rose is focused on obtaining the correct result for her clients regarding compensation and rehabilitation. Rose also has experience in dealing with cases that proceed to complex litigation.

Education

Rose’s Diploma in Counselling Skills from NUI Maynooth provides her with practical tools to support her clients throughout this process.

Recent News

The delay in publishing the report on the Lookback Review in North Kerry CAMHS is distressing for the affected families.

The North Kerry CAMHS Review led by Dr. Colette Halpin has completed its assessment of around 300 patient files, but the report remains unpublished despite being drafted in June 2025. This delay is causing significant distress for affected families, particularly given that 50% of reviewed cases have resulted in apologies from the HSE, compared to just 15% in the South Kerry Maskey Review.

Sodium Valproate Inquiry [2025]

The Sodium Valproate Inquiry in Ireland officially commenced on 22 July 2025, marking a crucial investigation into the historical use of this epilepsy drug and its devastating effects on children exposed in the womb. This comprehensive inquiry, chaired by Barrister Bríd O’Flaherty BL, will examine decades of prescribing practices, regulatory oversight, and the adequacy of patient warnings regarding Sodium Valproate’s risks to unborn children.